Pleural Effusions Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.70 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Pleural Effusions Treatment Market Analysis
The Pleural Effusions Treatment Market is poised to grow at a CAGR of 4.7% over the forecast period (2022 - 2027).
The Covid-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities. An increasing number of congestive heart failure, cancer, pneumonia, and pulmonary embolism during the pandemic increased the risk of pleural effusions among patients. Various research was conducted to find a correlation between Covid-19 infection and pleural effusion. For instance, the article 'Prevalence and Clinical Outcomes of Pleural Effusion in Covid-19 Patients: A Systematic Review and Meta-Analysis' published in January 2022 showed that pleural effusion is related to the risk and prognosis of Covid-19 disease. And pleural effusion can be used as a prognostic indicator to assess the likelihood of poorer outcomes in Covid-19 patients; as a result, the researchers of the above-mentioned research article advised that hospitalized Covid-19 patients with pleural effusion be handled promptly. These research and studies are predicted to have increased the demand for the treatment of pleural effusions during the pandemic. Thus, the pandemic is anticipated to show a considerable impact on the market studied.
Factors such as the increasing prevalence of pleural effusions and significant progress in the management of pleural effusions globally are expected to positively impact the market growth.
The rising prevalence of pleural effusions (PE) is one of the major factors that contribute to market growth. For instance, an article published by WebMD LLC in October 2021 stated that approximately 1.5 million pleural effusions are diagnosed in the United States every year and in industrialized countries, the estimated prevalence of pleural effusion is 320 cases per 100,000 people. This burden of the condition is creating demand for the availability of pleural effusion treatments globally. And it is expected to fuel the market growth during the analysis period.
Furthermore, the development activities by the market players in the form of product launches, acquisitions, mergers, and investments are also expected to enhance the market growth. For instance, in September 2021, BDR Pharma launched BIAPENEM to treat patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections. Biapenem is widely distributed and penetrates well into various tissues (e.g. lung tissue) and body fluids (e.g. sputum, pleural effusion, abdominal cavity fluid). Such advancements are expected to drive the market to grow in the future.
Therefore, owing to the above-mentioned factors the market studied is expected to grow over the forecast period. However, the partial success rate of treatments is anticipated to hinder market growth.
Pleural Effusions Treatment Market Trends
This section covers the major market trends shaping the Pleural Effusions Treatment Market according to our research experts:
Transudative Pleural Effusions Segment Shows Lucrative Opportunity in the Pleural Effusions Treatment Market
Transudative pleural effusion (TPE) fluid is similar to the fluid that one normally has in his/her pleural space. It forms from liquid leaking across the normal pleura. This type rarely needs to be drained unless it is very large. Congestive heart failure (CHF) is the most common cause of all pleural effusions in developed countries and accounts for the overwhelming majority of transudative pleural effusions. Thus, owing to the increasing CHF the segment is anticipated to grow over the forecast period.
A transudative pleural effusion develops when the systemic factors influencing the formation or absorption of the pleural fluid are altered. The pleural surfaces are not involved in the primary pathologic process. The diagnosis of transudative effusion is simple to establish by examining the characteristics of the pleural fluid. As per the article 'Randomised trial of indwelling pleural catheters for refractory transudative pleural effusions' published in February 2022, refractory symptomatic transudative pleural effusions are an indication of pleural drainage. And there has been supportive observational evidence for the use of indwelling pleural catheters (IPCs) for transudative effusions. Such research related to TPE is anticipated to create demand for innovative treatment which is expected to fuel segment growth.
Moreover, the article 'Transudative and Exudative Pleural Effusion in Chronic Kidney Disease Patients: A Prospective Single-Center Study' published in October 2021 stated that the common causes of transudative pleural effusion are fluid overload, heart failure, and nephrotic syndrome, while the causes for exudative pleural effusion are pneumonia, tuberculosis (TB), pulmonary embolisms, or diseases causing pleuro-renal syndromes, like systemic lupus erythematosus. As the burden of such diseases is increasing, the risk of TPE also increasing, which is creating demand for treatments available for TPE, thereby fuelling segment growth.
Therefore, owing to the factors mentioned above, the segment is anticipated to witness growth over the analysis period.
North America Dominates the Studied Market Over the Forecast Period
North America is anticipated to witness growth over the forecast period and dominate the market. Among other countries in the region, the United States is leading the market, due to factors such as an increase in healthcare expenditure, increasing research and developments, and a rising prevalence of heart diseases. Additionally, the rising geriatric population across the United States is the primary driver for the pleural effusions market.
For people with cancer and heart failure, pleural effusions are often malignant. The increasing burden of diseases in the United States is expected to create opportunities for the pleural effusions market. The data updated by the American Cancer Society's Cancer Statistics 2022, nearly 1.9 million new cancer cases are estimated to be diagnosed in the United States in the year 2022.
In addition, heart failure is a growing health and economic burden for the United States because of the aging population. As per the American Heart Association data updated in April 2022, nearly 115 million people have hypertension, 100 million have obesity, 92 million have prediabetes, 26 million have diabetes, and 125 million have atherosclerotic cardiovascular diseases (CVD) in the United States, which are known to be the risk factors for the development of heart failure. Thus, the high burden of cardiovascular diseases creates the risk of pleural effusions among the target population in the United States. This is expected to fuel market growth.
Therefore, owing to the increasing prevalence of pleural effusions, the market studied is anticipated to witness growth in the region.
Pleural Effusions Treatment Industry Overview
The pleural effusions treatment market is moderately competitive and consists of a few major players. Companies like B. Braun SE, Becton, Dickinson and Company, Bicakcilar, Biometrix, Cook Medical, Grena, Redax, Rocket Medical, and Smith Medical, among others, hold the substantial market share in the market.
Pleural Effusions Treatment Market Leaders
-
Becton, Dickinson and Company
-
Biometrix
-
Redax
-
Grena
-
B. Braun Melsungen
*Disclaimer: Major Players sorted in no particular order
Pleural Effusions Treatment Market News
- In April 2022, the study titled 'IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites' was registered in ClinicalTrials.gov for Malignant Pleural Effusion.
- In September 2021, Bristol Mayer Squibb declared three-year data from the CheckMate -743 trial. As per the clinical trial data, serious adverse reactions occurred in 54% of patients receiving OPDIVO plus YERVOY. The most frequent serious adverse reactions reported in 2% of patients were pneumonia, pyrexia, diarrhea, pneumonitis, pleural effusion, dyspnea, acute kidney injury, infusion-related reaction, musculoskeletal pain, and pulmonary embolism.
Pleural Effusions Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Pleural Effusions
4.2.2 Significant Progress in the Management of Pleural Effusions
4.3 Market Restraints
4.3.1 Partial Success Rate of Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Disease Type
5.1.1 Transudative
5.1.2 Exudative
5.2 By End User
5.2.1 Hospitals
5.2.2 Ambulatory Clinics
5.2.3 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 B. Braun SE
6.1.2 Becton, Dickinson and Company
6.1.3 Bicakcilar
6.1.4 Biometrix
6.1.5 Cook Medical
6.1.6 Grena
6.1.7 Redax
6.1.8 Rocket Medical
6.1.9 Smith Medical
6.1.10 Taiho Pharmaceutical Co., Ltd
6.1.11 Lung Therapeutics, Inc.
6.1.12 pfm medical ag
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Pleural Effusions Treatment Industry Segmentation
As per the scope of this report, the pleural effusion treatment is generally the therapy of pleural effusion, i.e. an abnormal collection of fluid between the thin layers of tissue (pleura) lining the lung and the wall of the chest cavity. The Pleural Effusions Treatment Market is segmented by Disease Type (Transudative and Exudative), End User (Hospitals, Ambulatory Clinics and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Disease Type | |
| Transudative | |
| Exudative |
| By End User | |
| Hospitals | |
| Ambulatory Clinics | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Pleural Effusions Treatment Market Research FAQs
What is the current Pleural Effusions Treatment Market size?
The Pleural Effusions Treatment Market is projected to register a CAGR of 4.70% during the forecast period (2024-2029)
Who are the key players in Pleural Effusions Treatment Market?
Becton, Dickinson and Company , Biometrix , Redax , Grena and B. Braun Melsungen are the major companies operating in the Pleural Effusions Treatment Market.
Which is the fastest growing region in Pleural Effusions Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Pleural Effusions Treatment Market?
In 2024, the North America accounts for the largest market share in Pleural Effusions Treatment Market.
What years does this Pleural Effusions Treatment Market cover?
The report covers the Pleural Effusions Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Pleural Effusions Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Non-Hodgkin Lymphoma Therapeutics Industry Report
Statistics for the 2024 Non-Hodgkin Lymphoma Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Non-Hodgkin Lymphoma Therapeutics analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
